| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2013-2019, 2008 | 3911 | 2008 |
| Cancer-related inflammation and treatment effectiveness CI Diakos, KA Charles, DC McMillan, SJ Clarke The Lancet Oncology 15 (11), e493-e503, 2014 | 1921 | 2014 |
| The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer GJK Guthrie, KA Charles, CSD Roxburgh, PG Horgan, DC McMillan, ... Critical reviews in oncology/hematology 88 (1), 218-230, 2013 | 1689 | 2013 |
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2006-2012, 2008 | 1098 | 2008 |
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ... The lancet oncology 13 (12), 1225-1233, 2012 | 640 | 2012 |
| Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study N Van Zandwijk, N Pavlakis, SC Kao, A Linton, MJ Boyer, S Clarke, ... The Lancet Oncology 18 (10), 1386-1396, 2017 | 597 | 2017 |
| Clinical pharmacokinetics of docetaxel SJ Clarke, LP Rivory Clinical pharmacokinetics 36, 99-114, 1999 | 579 | 1999 |
| Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer W Chua, KA Charles, VE Baracos, SJ Clarke British journal of cancer 104 (8), 1288-1295, 2011 | 547 | 2011 |
| A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer MJ Proctor, DC McMillan, DS Morrison, CD Fletcher, PG Horgan, ... British journal of cancer 107 (4), 695-699, 2012 | 533 | 2012 |
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 467 | 2018 |
| Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer ET Morgan, KB Goralski, M Piquette-Miller, KW Renton, GR Robertson, ... Drug Metabolism and Disposition 36 (2), 205-216, 2008 | 441 | 2008 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 383 | 2017 |
| High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy SCH Kao, N Pavlakis, R Harvie, JL Vardy, MJ Boyer, N van Zandwijk, ... Clinical cancer research 16 (23), 5805-5813, 2010 | 361 | 2010 |
| Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review EL Davis, B Oh, PN Butow, BA Mullan, S Clarke The oncologist 17 (11), 1475-1481, 2012 | 357 | 2012 |
| XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... British journal of cancer 105 (1), 58-64, 2011 | 314 | 2011 |
| Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ... JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019 | 307 | 2019 |
| Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial B Oh, P Butow, B Mullan, S Clarke, P Beale, N Pavlakis, E Kothe, L Lam, ... Annals of Oncology 21 (3), 608-614, 2010 | 299 | 2010 |
| Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy KA Slaviero, SJ Clarke, LP Rivory The lancet oncology 4 (4), 224-232, 2003 | 294 | 2003 |
| The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer JCY Chan, DL Chan, CI Diakos, A Engel, N Pavlakis, A Gill, SJ Clarke Annals of surgery 265 (3), 539-546, 2017 | 293 | 2017 |
| Diagnosis of gastrointestinal bleeding: A practical guide for clinicians BSM Kim, BT Li, A Engel, JS Samra, S Clarke, ID Norton, AE Li World journal of gastrointestinal pathophysiology 5 (4), 467, 2014 | 288 | 2014 |
Laurent Rivory在 unsw.edu.au 的电子邮件经过验证
